Clinical trial
A Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine (GBS-NN/NN2) After a Primary Vaccination of Healthy Pregnant Women, and to Assess Safety, Reactogenicity, and Immunogenicity of the GBS-NN/NN2 Vaccine When Administered During Follow-Up as a 1 Booster Dose During a New Pregnancy
NCT06592586 is registered in ClinicalTrials.gov with Minervax ApS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine (GBS-NN/NN2) After a Primary Vaccination of Healthy Pregnant Women, and to Assess Safety, Reactogenicity, and Immunogenicity of the GBS-NN/NN2 Vaccine When Administered During Follow-Up as a 1 Booster Dose During a New Pregnancy
- Lead sponsor
- Minervax ApS
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- March 7, 2025
- Completion date
- June 30, 2029
- Enrollment
- 137 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
bacterial infections, bacterial infections and mycoses, gram-positive bacterial infections, infections, meningitis, neonatal infection, neonatal sepsis, pneumonia, streptococcus agalactiae infection